TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression
Conferences
Secord, AA; Lewin, S; Method, M; Murphy, C
Published in: International Journal of Gynecological Cancer
December 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
International Journal of Gynecological Cancer
DOI
ISSN
1048-891X
Publication Date
December 2022
Volume
32
Start / End Page
A232 / A233
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Secord, A. A., Lewin, S., Method, M., & Murphy, C. (2022). TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression. In International Journal of Gynecological Cancer (Vol. 32, pp. A232–A233). Elsevier BV. https://doi.org/10.1136/ijgc-2022-igcs.528
Secord, Angeles Alvarez, Sharon Lewin, Michael Method, and Conleth Murphy. “TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression.” In International Journal of Gynecological Cancer, 32:A232–33. Elsevier BV, 2022. https://doi.org/10.1136/ijgc-2022-igcs.528.
Secord AA, Lewin S, Method M, Murphy C. TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression. In: International Journal of Gynecological Cancer. Elsevier BV; 2022. p. A232–3.
Secord, Angeles Alvarez, et al. “TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression.” International Journal of Gynecological Cancer, vol. 32, Elsevier BV, 2022, pp. A232–33. Crossref, doi:10.1136/ijgc-2022-igcs.528.
Secord AA, Lewin S, Method M, Murphy C. TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression. International Journal of Gynecological Cancer. Elsevier BV; 2022. p. A232–A233.
Published In
International Journal of Gynecological Cancer
DOI
ISSN
1048-891X
Publication Date
December 2022
Volume
32
Start / End Page
A232 / A233
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences